Live Breaking News & Updates on சுகாதாரம் தொழில் ஒழுங்குமுறை
Stay updated with breaking news from சுகாதாரம் தொழில் ஒழுங்குமுறை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Business Wire. The AP news staff was not involved in its creation. Healthcare Regulatory Partner Xavier Baker Joins Sheppard Mullin In Washington, D.C. April 14, 2021 GMT WASHINGTON (BUSINESS WIRE) Apr 14, 2021 Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that A. Xavier Baker has joined the firm’s Healthcare Industry Team as a partner in the Washington, D.C. office. Baker joins from Crowell & Moring LLP. “Our many industry-leading healthcare clients will benefit almost immediately from Xavier’s extensive capabilities to navigate through the complex emerging issues of mental health parity and to respond effectively to federally mandated parity audits,” said Sheppard Mullin managing partner MaryJeanette Dee. “His intimate understanding of the complicated regulatory world in which health plans and other industry players operate and his practical approach to advising healthcare clients on their compliance obli ....
WASHINGTON (AP) — One year after the nation was brought to a near-standstill by the coronavirus, President Joe Biden pledged in his first prime-time address Thursday night to make all ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, . Surface Oncology, Inc.March 9, 2021 GMT CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF388, an investigational antibody therapy targeting IL-27, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. This combination will be studied as a component of the first-in-human Phase 1 study of SRF388 and will be evaluated in patients with solid tumors, with a focus on patients ....
SEOUL, South Korea South Korea’s central bank says the country’s economy shrank for the first time in 22 years in 2020 as the coronavirus pandemic destroyed service industry jobs ....
Regulators in the U.K. and four other countries plan to fast-track the development of modified COVID-19 vaccines to ensure drugmakers are able to move swiftly in targeting emerging variants of the disease ....